<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Integrating RCTs, RWD, AI/ML and Statistics: Next-Generation Evidence Synthesis - Health AI Hub</title>
    <meta name="description" content="This perspective paper advocates for a next-generation evidence synthesis approach that princply integrates Randomized Controlled Trials (RCTs), Real-World Data">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Integrating RCTs, RWD, AI/ML and Statistics: Next-Generation Evidence Synthesis</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.19735v1" target="_blank">2511.19735v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-24
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Shu Yang, Margaret Gamalo, Haoda Fu
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> stat.ME, cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.19735v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.19735v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This perspective paper advocates for a next-generation evidence synthesis approach that princply integrates Randomized Controlled Trials (RCTs), Real-World Data (RWD), Artificial Intelligence/Machine Learning (AI/ML), and traditional statistics. This integration aims to overcome the individual limitations of these methods, such as RCT cost and external validity issues, RWD causal inference challenges, and AI/ML interpretability problems, to generate robust and transparent evidence essential for modern regulatory science.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This framework offers a critical pathway to accelerate and enhance the quality of clinical evidence, enabling more efficient drug development, broader applicability of trial results, and more informed regulatory approvals, ultimately leading to improved patient outcomes and more effective healthcare interventions.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper describes AI/ML applications in synthesizing evidence for clinical decision-making and drug development. This includes AI-assisted analysis within RCTs, leveraging AI/ML to integrate RWD with RCT findings to broaden applicability, designing hybrid controlled trials, and extending short-term clinical findings with long-term real-world data analysis. Essentially, AI/ML is used to enhance the rigor, scalability, and flexibility of evidence generation for medical treatments and interventions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>**Addressing Current Limitations**: RCTs are constrained by cost, duration, and restrictive eligibility criteria, limiting external validity, while RWD historically lacks reliability for establishing causality. AI/ML tools offer scalability but pose challenges in interpretability and rigor.</li>
                    
                    <li>**Call for Principled Integration**: The core argument posits that future evidence generation must move beyond 'RCTs vs. RWD' or 'statistics vs. AI/ML' towards their principled integration to leverage their respective strengths.</li>
                    
                    <li>**Causal Roadmap Necessity**: A clear causal roadmap is proposed as foundational for integration, ensuring explicit inferential goals, transparent assumptions, and clear tradeoffs in evidence synthesis.</li>
                    
                    <li>**Key Objectives & Applications**: Specific objectives for integrative evidence synthesis include transporting RCT results to broader populations, embedding AI-assisted analyses within RCTs, designing hybrid controlled trials, and extending short-term RCTs with long-term RWD.</li>
                    
                    <li>**Uniting Rigor and Innovation**: This integrative approach aims to combine statistical rigor with AI/ML innovation, addressing AI/ML's interpretability challenges while capitalizing on its scalability and flexibility.</li>
                    
                    <li>**Enhanced Regulatory Evidence**: The ultimate goal is to produce robust, transparent, and policy-relevant evidence, making integrated approaches a crucial component for modern regulatory decision-making and drug development.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The paper proposes an *integrative conceptual framework* rather than specific technical methods. It advocates for the principled combination of diverse evidence sources (RCTs, RWD) and analytical tools (traditional statistics, AI/ML) guided by a 'cusal roadmap.' This involves clarifying inferential goals, making assumptions explicit, and ensuring transparency about tradeoffs across different study designs and analytical approaches to overcome individual limitations.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary 'finding' or argument is that the optimal strategy for next-generation evidence synthesis lies in the principled integration of RCTs, RWD, AI/ML, and statistics. This integration effectively addresses the inherent limitations of each individual component, yielding more robust, transparent, and externally valid evidence crucial for drug development and regulatory decision-making.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This approach has the potential to significantly impact clinical practice by facilitating faster and more cost-effective drug development, providing more generalizable evidence to broader patient populations, enabling the design of adaptive and efficient clinical trials, and supporting better long-term monitoring of treatment safety and efficacy post-approval, leading to improved therapeutic strategies.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract highlights inherent limitations of current standalone approaches: RCTs suffer from cost, duration, and restrictive eligibility impacting external validity; RWD traditionally lacks strong causal inference capabilities; and AI/ML methods, while scalable, present challenges in interpretability and rigor when used in isolation. The paper implicitly aims to overcome these by proposing an integrated approach, rather than stating limitations of the integrative approach itself.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The authors outline specific future research directions including the development of privacy-preserving analytics for integrating diverse data, enhancing methods for robust uncertainty quantification in complex integrative analyses, and advancing small-sample methods relevant to comprehensive evidence synthesis.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Clinical Trials</span>
                    
                    <span class="tag">Regulatory Science (e.g., FDA, EMA)</span>
                    
                    <span class="tag">Pharmacovigilance</span>
                    
                    <span class="tag">Health Outcomes Research</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Randomized controlled trials (RCTs)</span>
                    
                    <span class="tag tag-keyword">Real-world data (RWD)</span>
                    
                    <span class="tag tag-keyword">Artificial intelligence (AI)</span>
                    
                    <span class="tag tag-keyword">Machine learning (ML)</span>
                    
                    <span class="tag tag-keyword">Evidence synthesis</span>
                    
                    <span class="tag tag-keyword">Causal inference</span>
                    
                    <span class="tag tag-keyword">Regulatory science</span>
                    
                    <span class="tag tag-keyword">External validity</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Randomized controlled trials (RCTs) have been the cornerstone of clinical evidence; however, their cost, duration, and restrictive eligibility criteria limit power and external validity. Studies using real-world data (RWD), historically considered less reliable for establishing causality, are now recognized to be important for generating real-world evidence (RWE). In parallel, artificial intelligence and machine learning (AI/ML) are being increasingly used throughout the drug development process, providing scalability and flexibility but also presenting challenges in interpretability and rigor that traditional statistics do not face. This Perspective argues that the future of evidence generation will not depend on RCTs versus RWD, or statistics versus AI/ML, but on their principled integration. To this end, a causal roadmap is needed to clarify inferential goals, make assumptions explicit, and ensure transparency about tradeoffs. We highlight key objectives of integrative evidence synthesis, including transporting RCT results to broader populations, embedding AI-assisted analyses within RCTs, designing hybrid controlled trials, and extending short-term RCTs with long-term RWD. We also outline future directions in privacy-preserving analytics, uncertainty quantification, and small-sample methods. By uniting statistical rigor with AI/ML innovation, integrative approaches can produce robust, transparent, and policy-relevant evidence, making them a key component of modern regulatory science.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>